Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome.

Understanding if divergent molecular profiles of DNA damage and repair (DDR) pathway activity, a biomarker of disease progression, exist in prostate tumors with favorable-risk features is an unmet need, which this study aim to unearth.

This was a multicenter registry genome-wide expression profiling study of prospectively collected radical prostatectomy (RP) tumor samples from 2014 to 2016. DDR activity was calculated from average expression of 372 DDR genes. Consensus hierarchical clustering was used to arrive at a robust clustering solution based on DDR gene expression patterns. Genome-wide differential expression between clusters was performed, and outcomes were evaluated across expression patterns.

Of 5239 patients from the prospective registry, 376 had favorable-risk disease (Grade group [GG] 1 to 2, PSA prior to RP <10ng/ml, pT2 or less). DDR activity score was correlated with prognostic genomic signatures that predict for metastatic risk (r = 0.37, P < 2e-16) and high grade groups (P < .001). High DDR activity (top-quartile) was observed in 28% of patients with favorable-risk disease. In favorable-risk disease, 3 distinct clusters with varied DDR activity emerged with consensus clustering. Cluster I (compared with cluster II-III and GG3-GG5 disease) had the highest expression of all DDR sub-pathways, MYC, PAPR1, AR, and AR activity (P < .001 for all). Furthermore, cluster I was associated with poorer metastasis-free survival (MFS) and Overall survival (OS) compared with other clusters (MFS; HR: 2.43, 95%CI, [1.22-4.83], P = .01; OS; HR: 2.77, 95%CI, [1.18-6.5], P = .01).

Cluster I is a novel subgroup of favorable-risk disease with high DDR activity, AR activity, PARP1 and chr8q/MYC expression, and poorer MFS and OS.

Clinical genitourinary cancer. 2022 Nov 16 [Epub ahead of print]

Nishwant Swami, Tiffany Nguyen, Ifeanyichukwu Ogobuiro, Matthew Abramowitz, Fallon Chipidza, Elai Davicioni, Karthik Meiyappan, Alan Dal Pra, Paul L Nguyen, Alan Pollack, Sanoj Punnen, Brandon A Mahal, Mohammed Alshalalfa

University of Massachusetts Medical School, Worcester, MA., University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL., Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA., Decipher Biosciences Inc., San Diego, CA., University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL. Electronic address: .